Results 41 to 50 of about 3,349,315 (392)
Engineering an anti-CD52 antibody for enhanced deamidation stability
mAbs, 2019 Deamidation evaluation and mitigation is an important aspect of therapeutic antibody developability assessment. We investigated the structure and function of the Asn-Gly deamidation in a human anti-CD52 IgG1 antibody light chain complementarity ...
Huawei Qiu +11 more
doaj +1 more source
Secukinumab in the treatment of psoriasis: patient selection and perspectives. [PDF]
, 2018 Secukinumab is a human monoclonal antibody targeting IL-17A that has been approved for three indications: moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.
Beck, Kristen M +2 more
core +1 more source
Acta otorhinolaryngologica italica, 2021 SUMMARY Chronic rhinosinusitis with nasal polyps (CRSwNP) is a heterogeneous inflammatory condition of nasal mucosa and paranasal sinuses, predominantly mediated by type 2 inflammation and often associated with comorbid asthma and/or Exacerbated ...
Eugenio de Corso +9 more
semanticscholar +1 more source
American Journal of Respiratory and Critical Care Medicine, 2019 &NA; Patients with severe uncontrolled asthma have disproportionally high morbidity and healthcare utilization as compared with their peers with well‐controlled disease.
M. McGregor +3 more
semanticscholar +1 more source
Biologics for the treatment of chronic rhinosinusitis with nasal polyps : state of the art [PDF]
, 2019 Chronic rhinosinusitis with nasal polyps (CRSwNP) is a complex upper airway disease affecting up to 11% of the population of Western Europe. In these western countries, 85% of the CRSwNP disease reveals a type 2 inflammatory pattern. In the last 15 years,
Bachert, Claus +3 more
core +1 more source
EUFOREA consensus on biologics for CRSwNP with or without asthma
Allergy. European Journal of Allergy and Clinical Immunology, 2019 Novel therapies such as type 2 targeting biologics are emerging treatment options for patients with chronic inflammatory respiratory diseases, fulfilling the needs of severely uncontrolled patients.
W. Fokkens +22 more
semanticscholar +1 more source
Feasibility of Discontinuing Biologics in Severe Asthma: An Algorithmic Approach
Journal of Asthma and Allergy, 2021 In severe asthma with type 2 (T2) inflammation, biologics targeting key mediators of T2 inflammation, including interleukin (IL)-5, IL-4/IL-13, and immunoglobulin (Ig)E, remarkably improve the management of severe asthma, providing new insights into the ...
K. Hamada +4 more
semanticscholar +1 more source
Scientific Reports, 2021 An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Anushikha Thakur +11 more
doaj +1 more source